Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide
Open Access
- 28 November 2022
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-9
Abstract
Objectives. The purpose of this study was to determine the predictive significance of pretreatment pan-immune-inflammation value (PIV) in patients with newly diagnosed glioblastoma multiforme (GBM) who received postsurgical radiation (RT) and concurrent plus adjuvant temozolomide (TMZ). Methods. The outcomes of 204 newly diagnosed GBM patients were analyzed retrospectively. Each eligible patient’s PIV was calculated using the findings of peripheral blood platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) counts obtained on the first day of therapy: . We used receiver operating characteristic (ROC) curve analysis to discover the ideal cutoff values for PIV concerning progression-free (PFS) and overall survival (OS) outcomes. The primary and secondary end-points were the OS and PFS divergences across the PIV groups. Results. In ROC curve analysis, the optimal PIV cutoff was 385, which substantially interacted with PFS and OS results and categorized patients into low PIV (L-PIV; ) and high PIV (H-PIV; ) groups. Comparative survival analyses showed that the patients in the H-PIV group had significantly shorter median PFS (6.0 vs. 16.6 months; ) and OS (11.1 vs. 22.9 months; ) durations than those in the L-PIV group. The results of multivariate Cox regression analysis indicated an independent and significant connection between an H-PIV measure and shorter PFS and OS outcomes. Conclusions. The novel PIV was able to independently stratify newly diagnosed GBM patients into two groups with fundamentally different PFS and OS outcomes following RT and concurrent plus adjuvant TMZ.Keywords
This publication has 47 references indexed in Scilit:
- Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2PLOS ONE, 2013
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survivalJournal of Neurosurgery, 2011
- Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like propertiesNeuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinibMolecular Oncology, 2007
- Atopy and Risk of Brain Tumors: A Meta-analysisJNCI: Journal of the National Cancer Institute, 2007
- Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cellsBlood, 2005
- Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cellsBlood, 2003
- Inflammation and cancerNature, 2002